CCXI:NSD-ChemoCentryx Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 50.72

Change

0.00 (0.00)%

Market Cap

USD 3.62B

Volume

2.89M

Avg Analyst Target

USD 58.60 (+15.54%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


CCXI Stock Forecast & Price:
Based on the ChemoCentryx Inc stock forecasts from 6 analysts, the average analyst target price for ChemoCentryx Inc is USD 58.60 over the next 12 months. ChemoCentryx Inc’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of ChemoCentryx Inc is Slightly Bearish, which is based on 3 positive signals and 6 negative signals. At the last closing, ChemoCentryx Inc’s stock price was USD 50.72. ChemoCentryx Inc’s stock price has changed by +0.40% over the past week, +123.63% over the past month and +262.29% over the last year.

About ChemoCentryx Inc (CCXI:NSD)

ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-08-14 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Inc

N/A

USD75.53B 24.40 16.33
REGN Regeneron Pharmaceuticals Inc

N/A

USD68.27B 12.89 9.72
MRNA Moderna Inc

N/A

USD66.97B 5.32 3.83
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BNTX BioNTech SE

N/A

USD38.59B 3.11 1.77
SGEN Seagen Inc

N/A

USD31.38B 55.02 -46.75
RPRX Royalty Pharma Plc

N/A

USD29.88B 43.33 20.93
ALNY Alnylam Pharmaceuticals Inc

N/A

USD28.07B N/A -36.52
GMAB Genmab AS

N/A

USD24.11B 75.33 6.42
ARGX argenx NV ADR

N/A

USD20.75B N/A -20.02

ETFs Containing CCXI

Symbol Name Weight Mer Price(Change) Market Cap
IWC iShares Micro-Cap ETF 0.00 % 0.60 %

N/A

USD1.05B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 39.30% 94% A 97% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 39.30% 94% A 97% A+
Trailing 12 Months  
Capital Gain 262.29% 100% A+ 99% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 262.29% 100% A+ 99% A+
Trailing 5 Years  
Capital Gain 618.41% 93% A 96% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 618.41% 93% A 96% A
Average Annual (5 Year Horizon)  
Capital Gain 109.09% 92% A- 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 109.09% 92% A- 95% A
Risk Return Profile  
Volatility (Standard Deviation) 214.29% 10% F 5% F
Risk Adjusted Return 50.90% 90% A- 83% B
Market Capitalization 3.62B 93% A 85% B
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 39.70 21% F 23% F
Price/Book Ratio 15.35 7% F 6% F
Price / Cash Flow Ratio -47.86 96% A 86% B
EV/EBITDA -26.66 98% A+ 91% A-
Management Effectiveness  
Return on Equity -46.96% 60% D- 25% F
Return on Invested Capital -34.26% 69% D+ 26% F
Return on Assets -18.55% 72% C- 23% F
Debt to Equity Ratio 1.65% 82% B- 85% B
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 5.43 43% F 34% F
Short Percent 11.42% 19% F 15% F
Beta 1.66 27% F 18% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector